ROCK2 and idiopathic pulmonary fibrosis: Zelasudil (Redx Pharma, Cheshire, UK), a next-generation ROCK2-preferential inhibitor, has shown anti-fibrotic activity in preclinical models and is currently under investigation in a phase II clinical trial for idiopathic pulmonary fibrosis.